Nothing unusual here , as expected they have ramped up their R&D on their product range and everyone was already aware of the CBZ impairment and rights issue costs.
Nothing more than an ASIC requirement.
Directors are happy to put $1.2M+ into the company, so am looking forward to this and next quarter